CPCarina Peres

Carina Peres

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Carina Peres has a total of 102 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Specialized Tfh cell subsets driving type-1 and type-2 humoral responses in lymphoid tissue

    by Saumya Kumar, Afonso P. Basto, Filipa Ribeiro, Silvia C. P. Almeida, Patricia Campos, Carina Peres, Sarwah Al-Khalidi, Anna Kilbey, Jimena Tosello, Eliane Piaggio, et al.

    Effective antibody responses are essential to generate protective humoral immunity. Different inflammatory signals polarize T cells towards an appropriate effector phenotype during an infection or immunization. Th1 and Th2 cells have been associated with the polarization of humoral responses for several decades. However, it is now established that T follicular helper cells (Tfh) have a unique ability to access the B cell follicle and support the Germinal Centre (GCs) responses by providing help to B cells. We investigated the specialization of Tfh cells induced under type-1 and type-2 conditions. We first studied homogenous Tfh cell populations generated by adoptively transferred TCR-transgenic T cells in mice immunized with type-1 and type-2 adjuvants. Using a machine learning approach, we established a gene expression signature that discriminates Tfh cells polarized towards type-1 and type-2 response, defined as Tfh1 and Tfh2 cells. The Tfh1 and Tfh2 distinct signature was validated against datasets of Tfh cells induced following LCMV or helminth infection. Using single-cell transcriptomics, we also dissected the heterogeneity of Tfh cells from the two immunizing conditions. Our results show that Tfh cells acquire a specialized function under distinct types of immune responses, but with the coexistence of a small population of Tfh cells of the alternative type. Furthermore, the specific molecular hallmarks of Tfh1 and Tfh2 cells identified herein offer putative new targets for tuning humoral responses.


  • Preclinical models and technologies to advance nanovaccine development

    by Carina Peres, Ana I. Matos, Liane I.F. Moura, Rita C. Acúrcio, Barbara Carreira, Sabina Pozzi, Daniella Vaskovich-Koubi, Ron Kleiner, Ronit Satchi-Fainaro, Helena F. Florindo


  • Immunization with mannosylated nanovaccines and inhibition of the immune-suppressing microenvironment sensitizes melanoma to immune checkpoint modulators

    by João Conniot, Anna Scomparin, Carina Peres, Eilam Yeini, Sabina Pozzi, Ana I. Matos, Ron Kleiner, Liane I. F. Moura, Eva Zupančič, Ana S. Viana, et al.

    A low response rate, acquired resistance and severe side effects have limited the clinical outcomes of immune checkpoint therapy. Here, we show that combining cancer nanovaccines with an anti-PD-1 antibody (αPD-1) for immunosuppression blockade and an anti-OX40 antibody (αOX40) for effector T-cell stimulation, expansion and survival can potentiate the efficacy of melanoma therapy. Prophylactic and therapeutic combination regimens of dendritic cell-targeted mannosylated nanovaccines with αPD-1/αOX40 demonstrate a synergism that stimulates T-cell infiltration into tumours at early treatment stages. However, this treatment at the therapeutic regimen does not result in an enhanced inhibition of tumour growth compared to αPD-1/αOX40 alone and is accompanied by an increased infiltration of myeloid-derived suppressor cells in tumours. Combining the double therapy with ibrutinib, a myeloid-derived suppressor cell inhibitor, leads to a remarkable tumour remission and prolonged survival in melanoma-bearing mice. The synergy between the mannosylated nanovaccines, ibrutinib and αPD-1/αOX40 provides essential insights to devise alternative regimens to improve the efficacy of immune checkpoint modulators in solid tumours by regulating the endogenous immune response.


  • Nanotechnology is an important strategy for combinational innovative chemo-immunotherapies against colorectal cancer

    by Ana I. Matos, Barbara Carreira, Carina Peres, Liane I.F. Moura, João Conniot, Thibaut Fourniols, Anna Scomparin, Águeda Martínez-Barriocanal, Diego Arango, João P. Conde, et al.


  • Functionalized branched polymers: promising immunomodulatory tools for the treatment of cancer and immune disorders

    by Liane I. F. Moura, Alessio Malfanti, Carina Peres, Ana I. Matos, Elise Guegain, Vanessa Sainz, Mire Zloh, María J. Vicent, Helena F. Florindo

    Well-defined synthetic branched nanostructures form an emerging subclass of macromolecular structures whose 3D structure and multivalency offer unique opportunities for fine-tuning internalization and cellular targeting. Dendrimers possess a well-defined 3D-globular backbone with highly versatile functional surface groups and exhibit a range of chemical and biological properties. Branched polymers present unique opportunities for the targeted delivery of diverse bioactive molecules (including targeting ligands, imaging probes, and drugs) via conjugation to multiple sites within the structure. The inherent versatility and multifunctionality of these architectures make them potentially useful for the modulation of multiple immune-related pathways for the treatment of a wide range of diseases and disorders, including cancer and human immunodeficiency virus infection. Herein, we describe the key components of the immune system whose targeting can help overcome immune-related disorders and discuss branched polymers (including dendrimers) as promising delivery systems with unique immunomodulatory properties against cancer and infectious diseases.


  • α-Galactosylceramide and peptide-based nano-vaccine synergistically induced a strong tumor suppressive effect in melanoma

    by Vanessa Sainz, Liane I.F. Moura, Carina Peres, Ana I. Matos, Ana S. Viana, Angela M. Wagner, Julia E. Vela Ramirez, Teresa S. Barata, Manuela Gaspar, Steve Brocchini, et al.


  • Open Access

    PO-415 Multivalent polymeric nanoparticles as an innovative cancer immunotherapy for colorectal cancer

    by A.I. Matos, C. Peres, L. Moura, B. Carreira, A.S. Viana, L. Graça, R. Gaspar, J.P. Conde, H.F. Florindo

    Introduction Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the fourth cause of cancer death worldwide. It is respossible for approximately 7 00 000 deaths per year. This work focused on the development of a combinatorial multivalent nanoplatform for CRC immunotherapy and immunomodulation based on the design of polymeric nanoparticles (NP) able to deliver a combination of CRC-associated antigen, adjuvants and gene regulators according to targeted cells, dendritic cell (DC) and CRC cells. Material and methods Poly(lactic-co-glycolic) (PLGA)-based NP were prepared by the double emulsion (w/o/w) solvent evaporation method. NP were physicochemically characterised in terms of size, zeta potential and surface morphology. CRC antigen loadings were quantified by fluorescence. Immature DC (ATCC® CRL-11904TM) were used to evaluate the in vitro NP cytotoxicity by the propidium iodide assay, as well as NP cellular uptake profile by flow cytometry. In vivo biodistribution assay of plain NP was also performed using the IVIS Lumina® Bioimaging system. NP uptake in vivo by myeloid antigen presenting cells and the expression of maturation and co-stimulatory molecules at the surface of these cells sorted within draining lymph nodes, were also evaluated by flow cytometry. Results and discussions PLGA-based NP presented a mean size diameter close to 200 nm, with low polydispersity index (PdI) (≤0.200), a surface charge close to neutrality, as well as, a spherical shape and smooth surface. These multivalent delivery systems presented high loadings for antigen and adjuvants. No cytotoxic effect was observed on immature DC up to 48 hour of incubation. NP were extensively internalised by immature DC in vitro after 48 hour incubation, and by migratory DC in vivo 17 hour after animal immunisation. In vivo real-time monitoring of NP accumulation in mice whole bodies and dissected organs showed a fluorescent signal at 17 hour close to the site of immunisation and in the lymph nodes. No significant differences in the expression of the co-stimulatory CD80, CD86 and MHC class I markers on CD11b+CD11c+MHCII+ population at lymph nodes were observed among different polymeric combinations upon mice immunisation with NP carrying CRC antigen and adjuvant. Conclusion According to NP physicochemical characteristics, internalisation and biodistribution patterns, this innovative nanoplatform can lead to a safe multivalent nanomedicine able to modulate dendritic cell activity and T cell expansion against tumour cells expressing entrapped antigens.

  • Open Access

    PO-416 A novel multifunctional polypeptide-based platform as an immunotherapeutic approach for melanoma

    by L. Moura, A. Duro-Castano, C. Peres, E. Gallon, A. Matos, M.J. Vicent, H. Florindo

    Introduction Melanoma is the most dangerous type of skin cancer and novel treatments are needed. Alternative therapeutics should be devised isolated or in combination with targeted immunotherapies, to efficiently stimulate specific anti-tumour responses. Branched polypeptides exhibit advanced engineered complexity and unique structural properties inaccessible to linear polymers that make them ideal drug delivery systems with enhanced biological performance. Branched nanosystems have the ability to activate immune cells, as dendritic cells (DC) and natural killer (NK) cells, constituting potential platforms to modulate the release profile of loaded molecules, including tumour associated antigens (TAA), adjuvants and drugs. This work aims to evaluate the in vivo anti-tumour efficacy of peptide-1 -conjugated polypeptide (pept-1-BP), with special emphasis on their impact on the modulation of the immune cell function. Material and methods BP were synthesised and conjugated with the peptide-1 (pept-1-BP) via reductive-sensitive disulfide linker. To address in vitro and in vivo studies, Cy5.5 was conjugated to platform. To evaluate the effect of the conjugate on melanoma tumour growth, B16.F10 cells were implanted subcutaneously into C57BL/6 mice. At day 7, animals were injected with two doses (1 week apart) of 100 µL of PBS, Toll-like receptor ligands CpG (20 µg/dose) and Poly I:C (40 µg/dose) in solution, BP backbone (575 µg/dose) and pept-1-BP (575 µg/dose) mixed with adjuvants. Every 2 days, weight of the mice and tumour growth was followed. At day 21, mice were sacrificed and tumour and lymph nodes were collected. A cell suspension from tumour cells and lymph nodes of each animal was prepared and analysed for infiltrated lymphocytes (CD45.1, CD3e, CD8α, CD4, CD107, PD-1, CTLA-4) by flow cytometry. Results and discussions The BP presented a size of 81.86±1.63 nm and a zeta potential of −45.10±1.72 mV, while pept-1-BP showed a mean average diameter of 104.1±2.21 nm and a zeta potential of −24.8±0.64 mV, with a pept-1 loading efficiency of 8.7% (w/w). In vivo results showed a significant reduction of tumour size in conjugate treated mice compared with the other groups. In addition, the FACS analysis of infiltrating lymphocytes within tumour site evidenced an increased expression for CD4, CD8α and NK cells. Conclusion Overall, our results support the promising use of this novel conjugate for the delivery of TAA, as an effective anti-tumour immune therapeutic strategy able to decrease and control of tumour growth.

  • Functional Moieties for Intracellular Traffic of Nanomaterials

    by Ana L. Silva, Liane I.F. Moura, Bárbara Carreira, João Conniot, Ana I. Matos, Carina Peres, Vanessa Sainz, Liana C. Silva, Rogério S. Gaspar, Helena F. Florindo